

To
The Bombay Stock Exchange Limited

Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001

Kind Attn.: Mr. Gopal K Iyer

**The National Stock Exchange of India
Limited**

Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai 400 051

Kind Attn.: Mr. Hari K.

Dear Sirs,

Sub.: Intimation of Audited Financial Results of Plethico Pharmaceuticals Limited for the year ended March 31, 2015.

Ref: Clauses 16, 20 and 41 of the Listing Agreements

We would like to inform you that the Board of Directors at their meeting held today i.e. Monday the 14th day of March, 2016, inter-alia, approved the Audited (Standalone and Consolidated) Financial Results of the Company, for the year ended 31st March, 2015.

A copy of the said results along with the reports issued by the Statutory Auditors of Company is enclosed herewith. Further please note that the said results and the said reports shall be uploaded on the website of the company i.e. www.plethico.com and will be published in the newspaper as per clause 41 of the Listing Agreement.

This is for your information and record.

Thanking You

Yours Sincerely,

For PLETHICO PHARMACEUTICALS LIMITED

SHASHIKANT PATEL

Chairman cum Managing Director
(Din: 00199120)



PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) **Tel.:** +91-731-2806275, +91-731-2806271

Website : www.plethico.com **E-mail :** info@plethico.com **CIN No.** L24232MP1991PLC006801

AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2015											
(Rs. in Lakh, except share data, per share data and unless otherwise stated)											
Sr. No.	Particulars	Standalone Financials					Consolidated Financials				
		3 Month Ended			Year Ended	15 Month Ended (Refer to Note)	3 Month Ended			Year Ended	15 Month Ended (Refer to Note)
		31.3.2015	31.12.2014	31.3.2014	31.3.2015	31.03.2014	31.3.2015	31.12.2014	31.3.2014	31.3.2015	31.03.2014
		(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Income from Operations										
a)	Net Sales/Income from Operations	1,407.59	1,739.56	6,527.38	12,952.10	53,129.64	11,358.08	10,819.56	31,301.64	75,793.40	205,979.91
b)	Other Operating Income	(89.92)	325.33	(325.54)	710.80	3,652.46	(73.80)	325.33	(279.18)	719.90	3,863.40
	Total Income from operations (1+2)	1,317.67	2,064.89	6,201.84	13,662.90	56,782.10	11,284.28	11,144.89	31,022.46	76,513.30	209,843.31
2	Expenses	-	-	-	-	-	-	-	-	-	-
a)	Cost of Material Consumed	369.09	522.62	2,421.59	5,811.60	19,378.53	1,794.12	522.62	6,708.36	15,421.90	37,638.91
b)	Purchase of Finished goods	102.24	57.08	1,405.98	1,908.90	21,919.89	5,697.89	4,988.67	8,445.47	25,728.50	87,290.26
c)	(Increase) / Decrease in Stock in trade & work in progress	140.62	118.81	98.32	366.40	543.94	653.96	744.26	1,294.54	2,413.50	(862.21)
d)	Employees Cost	622.82	661.37	580.37	2,675.30	3,370.37	1,487.74	935.27	3,043.89	8,548.60	15,959.71
e)	Depreciation/Amortization	664.60	203.00	208.79	1,273.60	1,039.79	1,642.56	1,082.47	1,578.57	5,790.20	6,422.85
f)	Other Expenditure	422.33	593.18	1,167.67	2,385.00	5,160.65	2,378.57	2,120.44	6,681.35	13,065.70	37,776.68
	Total Expenses	2,321.70	2,156.06	5,882.72	14,420.80	51,413.17	13,654.83	10,393.72	27,752.18	70,968.40	184,226.19
3	Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)	(1,004.03)	(91.17)	319.12	(757.90)	5,368.92	(2,370.55)	751.17	3,270.28	5,544.90	25,617.12
4	Other income	3.46	12.62	46.36	-	78.31	(15.27)	12.62	-	-	-
5	Profit (+)/ Loss (-) from Ordinary Activities before finance costs and exceptional items (3+4)	(1,000.57)	(78.56)	365.48	(757.90)	5,447.23	(2,385.82)	763.79	3,270.28	5,544.90	25,617.12
6	Finance Costs	2,159.65	1,157.36	1,211.74	5,440.60	6,276.66	2,159.73	1,170.36	5,701.64	12,154.90	15,932.25
7	Profit / Loss from Ordinary Activities after finance costs but before exceptional items (5+6)	(3,160.22)	(1,235.92)	(846.26)	(6,198.50)	(829.43)	(4,545.55)	(406.58)	(2,431.36)	(6,610.00)	9,684.87
8	Exceptional items (Refer Note below)	31,955.80	-	-	31,955.80	-	31,955.80	-	-	31,955.80	-
9	Profit / Loss from Ordinary Activities before tax (7-8)	(35,116.02)	(1,235.92)	(846.26)	(38,154.30)	(829.43)	(36,501.35)	(406.58)	(2,431.36)	(38,565.80)	9,684.87
10	Tax expense	10,793.60	-	1.11	10,793.60	43.76	11,653.10	-	(1,232.93)	10,793.60	(1,383.82)
11	Net Profit / Loss from Ordinary Activities after tax (9-10)	(24,322.42)	(1,235.92)	(847.37)	(27,360.70)	(873.18)	(26,567.25)	(406.58)	(1,198.43)	(27,772.20)	11,068.69
12	Extra-Ordinary Items (net of tax expense)	-	-	-	-	-	-	-	-	-	-
13	Net Profit / Loss for the period (11+12)	(24,322.42)	(1,235.92)	(847.37)	(27,360.70)	(873.18)	(26,567.25)	(406.58)	(1,198.43)	(27,772.20)	11,068.69
14	Share of profit / (Loss) of associates	-	-	-	-	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-	-	-	-	-
16	Net Profit / Loss after taxes, minority interest and share of profit / (Loss) of associates (13+14+15)	(24,322.42)	(1,235.92)	(847.37)	(27,360.70)	(873.18)	(26,567.25)	(406.58)	(1,198.43)	(27,772.20)	11,068.69
17	Paid-up equity share capital (Nominal Value - Rs. 10/- each)	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67	3,406.67
18	Reserves excluding Revaluation reserves as per balance sheet of previous accounting year	-	-	-	22,496.90	50,456.02	-	-	-	138,015.90	157,975.87
19.i	Earning/(loss) per share (before Extra-Ordinary items) (not to be annualized) (Rs.)		-	-	-	-	-	-	-	-	-
	Basic	(71.40)	(3.63)	(2.49)	(80.32)	(2.56)	(77.99)	(1.19)	(3.52)	(81.52)	32.49
	Diluted	(71.40)	(3.63)	(2.49)	(80.32)	(2.56)	(58.28)	(1.19)	(3.52)	(81.52)	32.49
19.ii	Earning/(loss) per share (After-Ordinary items) (not to be annualized) (Rs.)										
	Basic	(71.40)	(3.63)	(2.49)	(80.32)	(2.56)	(58.28)	(1.19)	(3.52)	(81.52)	32.49
	Diluted	(71.40)	(3.63)	(2.49)	(80.32)	(2.56)	(58.28)	(1.19)	(3.52)	(81.52)	32.49
A	PARTICULARS OF SHAREHOLDING										
1	Public Shareholding										
a)	Number of equity shares	9645975	9645975	8965737	9645975	8965737	9645975	9645975	8965737	9645975	8965737
b)	Percentage of Shareholding	28.31%	28.31%	26.32%	28.31%	26.32%	28.31%	28.31%	26.32%	28.31%	26.32%
2	Promoter and Promoter Group Shareholding :										
a)	Pledged/Encumbered										
-	Number of shares	20937385	20937385	21621885	20937385	21621885	20937385	20937385	21621885	20937385	21621885
-	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	85.74%	85.74%	86.14%	85.74%	86.14%	85.74%	85.74%	86.14%	85.74%	86.14%
-	- Percentage of shares (as a % of the total share capital of the Company)	61.46%	61.46%	63.47%	61.46%	63.47%	61.46%	61.46%	63.47%	61.46%	63.47%
b)	Non-encumbered										
-	Number of shares	3483307	3483307	3479045	3483307	3479045	3483307	3483307	3479045	3483307	3479045
-	-Percentage of Shares (as a % of total shareholding of promoter and promoter group)	14.26%	14.26%	13.86%	14.26%	13.86%	14.26%	14.26%	13.86%	14.26%	13.86%
-	- Percentage of shares (as a % of the total share capital of the Company)	10.22%	10.22%	10.21%	10.22%	10.21%	10.22%	10.22%	10.21%	10.22%	10.21%
B	INVESTOR COMPLAINTS										
	3 Month Ended										
	31.03.2015										
	Pending at the beginning of the quarter										
	Received during the quarter										
	Disposed of during the quarter										
	Remaining unresolved at the end of the quarter										

PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) Tel.: +91-731-2806275, +91-731-2806271

Website : www.plethico.com E-mail : info@plethico.com CIN No. L24232MP1991PLC006801



Note :-

1. The above audited Financial Results for the quarter ended **31ST March, 2015** were approved at the meeting of the Board of Directors held on 14th March, 2016, after being approved and recommended by the Audit Committee.
2. The depreciation has been calculated based on estimation of useful life of Assets as prescribed under schedule II of The Companies Act 2013 further year 2014-15. The effect of this change has been reflected in the fourth quarter of the financial year 2014-15 and appropriate adjustments have been made to the general reserves.
3. The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.
4. The EPS has been computed in accordance with the accounting standards (AS-20) issued by the ICAI.
5. Figures of the previous quarter / year wherever necessary have been regrouped and reclassified to confirm to those of the current quarter.
6. The cost of Packing materials has been included in Material cost.
7. The consolidated financial results of quarter / 12 month ended 31st March, 2015 comprises of its aforesaid subsidiaries and step-down subsidiaries. The financial results of the subsidiaries has been regrouped and / or reclassified wherever as per the requirements of Indian GAAP.
8. During quarter ending 31st December 2014, company's step down subsidiary Natrol Inc, USA was put to auction for a section 363 sale by the United state court for the district of Delaware. The process of auction deal is about to conclude as per prescribed procedures. However the company has provided for loss on diminution of investment in Natrol Inc. USA which has been disclosed as an **Exceptional** item in Point No 8
9. The Company had issued Foreign Currency Convertible Bonds(FCCB) on October 22, 2007 which were due for repayment on October 23, 2012 or alternatively, the same was required to be converted into equity shares of the Company. **Disputes had arisen between the Company, Trustee and bond holders and pursuant to which the Company had filed a suit for damages against Trustees for USD150million** and a suit for damages against one of the purported Bond holder for USD250million at District Court, Indore Madhya Pradesh. In consequence thereof, the Trustees had filed a winding up petition against the Company which is pending interalia for further orders. The company has disputed the amount claimed by the Trustee on various grounds. Company has obtained Relief Undertaking certificate from MP Government on June 16, 2015 and had filed an intervention appeal in Indore High Court to stay/suspend all litigation going against the company. The Company received stay from Hon'ble High Court of Indore on September 15, 2015. The prime objective of the Relief Undertaking certificate issued by Madhya Pradesh Government is to ensure continuous running of the facility and continuous employment of labour.
10. **CDR Package Implementation:** Master Restructuring Agreement (MRA) got signed in the month of March 2015. Post MRA documentation were to be completed by April 13, 2015, however since the winding up order was passed on April 07, 2015 appointing Provisional Liquidator for the company, the Company did not had power/ authority to enter into any new agreement or sign any document on behalf of the company. Post MRA documentation are pending to be completed, which were not completed since the stay on liquidation proceeding was not available. The stay from Hon'ble High Court of Indore was received on September 15, 2015, post which Company has requested all the bankers in the JLM meeting held on September 25, 2015 to decide a mutual date for signing of the Post-MRA documents. Promoter's, Bankers along with CDR EG are having continuous meetings with Bank of Baroda for requesting them to participate in the CDR package and complete the implementation of the package at the earliest
11. The Company has not provided for contingent liabilities, including contingent tax liabilities in its books.

For PLETHICO PHARMACEUTICALS LIMITED

Date : 14.03.2016
Place : Mumbai

SHASHIKANT PATEL
CHAIRMAN & MANAGING DIRECTOR



PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) Tel.: +91-731-2806275, +91-731-2806271

Website : www.plethico.com E-mail : info@plethico.com CIN No. L24232MP1991PLC006801

Sr. No.	Particulars	Standalone		Consolidated	
		as at		as at	
		31.03.2015	31.03.2014	31.03.2015	31.03.2014
		Audited	Audited	Audited	Audited
A	EQUITY & LIABILITIES				
1	Shareholder's Fund				
	a) Share Capital				
	b) Reserves & Surplus	3,406.70	3,406.67	3,406.70	3,406.67
	c) Money received against share warrants	22,496.90	50,456.00	138,015.90	157,979.50
		25,903.60	53,862.67	141,422.60	161,386.17
2	Share application money pending allotment				
3	Minority Interest				
4	Non Current Liabilities				
	a) Long term borrowings				
	b) Deferred tax liabilities	20,683.20	5,896.69	45,399.40	47,057.52
	c) Other long term liabilities		1,723.74		1,798.12
	d) Long term provisions	2,280.50	2,048.37	2,280.50	2,250.32
5	Current Liabilities	22,963.70	9,668.80	47,679.90	51,105.96
	a) Short-term borrowings				
	b) Trade Payables	13,431.50	20,500.56	20,145.80	20,563.47
	c) Other current liabilities	1,856.20	2,235.60	2,391.80	10,948.06
	d) Short term provisions	82,604.20	77,865.15	87,408.90	81,195.10
		6,332.30	6,220.07	6,457.10	6,256.84
	TOTAL EQUITY AND LIABILITIES	104,224.20	106,821.38	116,403.60	118,963.47
B	ASSETS	153,091.50	170,352.86	305,506.10	331,455.60
1	Non-current assets				
	a) Tangible Assets				
	b) Intangible Assets	10,028.70	11,863.10	10,100.90	12,668.73
	i) Goodwill on Consolidation			47,487.40	58,939.00
	c) Non-current investments			26,997.40	26,997.40
	d) Deferred tax assets (Net)	48,700.10	80,655.91	19,896.00	19,896.00
	e) Long term loans and advances	9,069.90		9,069.90	
	f) Other non-current assets				1,825.77
2	Current assets	67,798.70	92,519.01	113,611.70	142,687.25
	a) Current investments				
	b) Inventories				
	c) Trade Receivables	1,010.40	1,660.92	4,603.00	20,278.23
	d) Cash and cash equivalents	78,848.90	69,953.39	121,910.90	111,636.45
	e) Short term loans and advances	1,197.30	1,385.40	26,191.90	3,401.54
	f) Other current assets	4,236.20	4,834.14	37,381.90	51,751.57
				1,806.70	1,700.56
	TOTAL ASSETS	85,292.80	77,833.85	191,894.40	188,768.35
		153,091.50	170,352.86	305,506.10	331,455.60

Sr No

- The above audited financial results for the quarter and year ended 31 March 2015 were approved at the meeting of the Board of Directors held on 14th March, 2016, after being approved and recommended by the Audit Committee.
- Figures pertaining to last quarter are balancing figure between audited figure in respect of the year ended 31st March 2015 and published year to date figure upto 31 Dec 2014.
- The company is engaged in single segment viz Pharmaceutical which is governed by same set of risk and returns, therefore the Accounting standard AS 17 on "Segment Reporting" issued by ICAI, is not applicable.
- The EPS has been computed in accordance with the Accounting Standard AS 20 issued by the ICAI.
- Figures of the previous quarter / year wherever necessary have been regrouped and reclassified to confirm to those of the current quarter.
- The cost of packing material has been included in material cost.
- The financial statements of the subsidiaries are audited by the auditors of the subsidiaries as on the Reporting date. In terms of accounting standard 21, adjustments have been made for significant transactions of these subsidiaries for the period from 1st January 2015 to 31st March 2015 on the basis of their management accounts for the said period for consolidation of financial statements with that of the parent company.
- The Company had issued Foreign Currency Convertible Bonds (FCCB) on October 22, 2007 which were due for repayment on October 23, 2012 or alternatively, the same was required to be converted into equity shares of the Company. Disputes had arisen between the Company, Trustee and bond holders and pursuant to which the Company had filed a suit for damages against Trustees for USD 150 million and a suit for damages against one of the purported Bond holder for USD 250 million at District Court, Indore Madhya Pradesh. In consequence thereof, the Trustees had filed a winding up petition against the Company which is pending inter alia for further orders. The company has disputed the amount claimed by the Trustee on various grounds. Company has obtained Relief Undertaking certificate from MP Government on June 16, 2015 and had filed an intervention appeal in Indore High Court to stay/suspend all litigation going against the company. The Company received stay from Hon'ble High Court of Indore on September 15, 2015. The prime objective of the Relief Undertaking certificate issued by Madhya Pradesh Government is to ensure continuous running of the facility and continuous employment of labour.
- CDR Package Implementation:** Master Restructuring Agreement (MRA) got signed in the month of March 2015. Post MRA documentation were to be completed by April 13, 2015, however since the winding up order was passed on April 07, 2015 appointing Provisional Liquidator for the company, the Company did not had power/ authority to enter into any new agreement or sign any document on behalf of the company. Post MRA documentation are pending to be completed, which were not completed since the stay on liquidation proceeding was not available. The stay from Hon'ble High Court of Indore was received on September 15, 2015, post which Company has requested all the bankers in the JLM meeting held on September 25, 2015 to decide a mutual date for signing of the Post-MRA documents. Promoter's, Bankers along with CDR EG are having continuous meetings with Bank of Baroda for requesting them to participate in the CDR package and complete the implementation of the package at the earliest.
- The company has not provided for contingent liabilities, including contingent tax liabilities in its books.

Date: 14.03.2016
Place: Mumbai

For Plethico Pharmaceuticals Limited

Shashikant Patel
Chairman & Managing Director

PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) Tel.: +91-731-2806275, +91-731-2806271
Website : www.plethico.com E-mail : info@plethico.com CIN No. L24232MP1991PLC006801





Annexure VII to Clause 41

When an Unqualified Opinion is Expressed on the Quarterly Financial Results (for companies other than banks)

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of Plethico Pharmaceuticals Limited

We have audited the quarterly financial results of Plethico Pharmaceuticals Limited for the quarter ended 31st March, 2015 and the year to date results for the period 1st April, 2014 to 31st March, 2015, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net loss and other financial information for the quarter ended 31st March, 2015 as well as the year to date results for the period from 1st April, 2014 to 31st March, 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.


Place: Mumbai

Date: 14th March, 2016



For Chaturvedi & Kotecha

Chartered Accountants
(Firm Reg. No.: 115676W)


CA Ashok Kumar Chaturvedi
Partner
Membership No. 036913